Butyrophilin-Like Protein 2 (BTNL2) Antibody
169€ (20 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Butyrophilin-Like Protein 2 (BTNL2) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx317938
tested applications
ELISA, WB, IHC
Description
BTNL2 Antibody is a Rabbit Polyclonal against BTNL2.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Butyrophilin-Like Protein 2 (BTNL2) |
| Host | Rabbit |
| Reactivity | Human, Mouse |
| Recommended Dilution | WB: 1/2000 - 1/10000, IHC: 1/20 - 1/200. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Unconjugated |
| Isotype | IgG |
| Purity | > 95% |
| Purification | Purified by Protein G. |
| Size 1 | 20 µg |
| Size 2 | 50 µg |
| Size 3 | 100 µg |
| Size 4 | 200 µg |
| Size 5 | 1 mg |
| Form | Liquid |
| Tested Applications | ELISA, WB, IHC |
| Buffer | 0.01 M PBS, pH 7.4, 0.03% Proclin-300 and 50% Glycerol. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | Q9UIR0 |
| Gene ID | 56244 |
| NCBI Accession | NP_001291490.1 |
| OMIM | 606000 |
| Alias | SS2,BTN7,BTL-II,HSBLMHC1,Butyrophilin-like protein 2 |
| Background | Antibody anti-BTNL2 |
| Status | RUO |
Descripción
Butyrophilin like 2 (BTNL2) is an immunomodulatory protein expressed in epithelial and lymphoid tissues. BTNL2 interacts with T cells, modulating their activation and proliferation, thus playing a key role in maintaining immune homeostasis and preventing excessive immune responses. Genetic polymorphisms in BTNL2 are linked to susceptibility to autoimmune diseases, including sarcoidosis, rheumatoid arthritis, and Crohn's disease, as well as some cancers. Its expression in mucosal tissues suggests a role in regulating local immune responses to pathogens and maintaining the epithelial barrier. BTNL2's therapeutic potential is under investigation, particularly its ability to influence immune tolerance and suppress aberrant immune activation in inflammatory diseases and transplant rejection.
